-
公开(公告)号：US11717567B2
公开(公告)日：2023-08-08
申请号：US17194779
申请日：2021-03-08
发明人： SangKon Oh , Sandra Zurawski , Gerard Zurawski
IPC分类号： A61K39/12 , A61K39/395 , C07K14/025 , C07K16/28 , C07K14/005 , C12N7/00 , A61K39/00
CPC分类号： A61K39/12 , A61K39/395 , A61K39/3955 , A61K39/39541 , C07K14/005 , C07K16/2878 , C12N7/00 , A61K2039/505 , A61K2039/53 , A61K2039/55511 , A61K2039/585 , A61K2039/6056 , A61K2039/70 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2319/74 , C07K2319/91 , C12N2710/20034
摘要： Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
-
公开(公告)号：US20170106051A1
公开(公告)日：2017-04-20
申请号：US15311572
申请日：2015-05-15
发明人： SangKon Oh , Sandra Zurawski , Hyemee Joo , Gerard Zurawski
CPC分类号： A61K38/2066 , A61K39/0008 , A61K2039/505 , A61K2039/54 , A61K2039/57 , C07K14/5428 , C07K16/2851 , C07K16/2878 , C07K2317/24 , C07K2317/40 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2319/00
摘要： Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.
-
公开(公告)号：US09567401B2
公开(公告)日：2017-02-14
申请号：US14165400
申请日：2014-01-27
IPC分类号： A61K39/395 , C07K16/28 , C07K14/005 , A61K39/00
CPC分类号： C07K16/2878 , A61K39/00 , A61K2039/6056 , C07K14/005 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/74 , C07K2317/80 , C07K2319/00 , C12N2740/16222 , C12N2740/16322
摘要： The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
摘要翻译： 本发明包括用于表达，分泌和使用用作例如疫苗和抗原递送载体的用于将抗原递送至抗原呈递细胞的组合物和方法。 在一个实施方案中，载体是抗CD40抗体或其片段，以及与抗-CD40抗体或其片段（包括人源化抗体）连接的一个或多个抗原肽。
-
公开(公告)号：US09339556B2
公开(公告)日：2016-05-17
申请号：US13927437
申请日：2013-06-26
CPC分类号： A61K47/48369 , A61K2039/5154 , A61K2039/55516 , C07K16/28 , C07K2317/92 , C07K2319/01 , C07K2319/33
摘要： The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies.
-
公开(公告)号：US11957734B2
公开(公告)日：2024-04-16
申请号：US17301123
申请日：2021-03-25
发明人： SangKon Oh , Sandra Zurawski , Hyemee Joo , Gerard Zurawski
CPC分类号： A61K38/2066 , A61K39/0008 , C07K14/5428 , C07K16/2851 , C07K16/2878 , A61K2039/505 , A61K2039/54 , A61K2039/57 , C07K2317/24 , C07K2317/40 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2319/00
摘要： Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.
-
公开(公告)号：US20220340670A1
公开(公告)日：2022-10-27
申请号：US17687971
申请日：2022-03-07
IPC分类号： C07K16/28 , C07K14/005
摘要： The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
-
公开(公告)号：US11219683B2
公开(公告)日：2022-01-11
申请号：US16946390
申请日：2020-06-19
申请人： INSERM (Institut National de la Santé et de la Recherche Mêdicale) , Baylor Research Institute , Universite Paris Est Creteil Val De Marne , Assistance Publique Hopitaux de Paris
发明人： Yves Levy , Gerard Zurawski , Sandra Zurawski , Anne-Laure Flamar
IPC分类号： A61K39/00 , A61K39/12 , A61K39/21 , A61P31/18 , C07K14/005 , C12N7/00 , C07K16/28 , C07K16/10
摘要： Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
-
公开(公告)号：US20190184008A1
公开(公告)日：2019-06-20
申请号：US16141157
申请日：2018-09-25
申请人： INSERM (Institut National de la Santé et de la Recherche Mêdicale , Baylor Research Institute , Universite Paris Est Creteil Val De Marne , Assistance Publique Hopitaux de Paris
发明人： Yves Levy , Gerard Zurawski , Sandra Zurawski , Anne-Laure Flamar
IPC分类号： A61K39/21 , C07K16/28 , A61P31/18 , C07K14/005 , C12N7/00
CPC分类号： A61K39/21 , A61K2039/505 , A61K2039/572 , A61K2039/575 , A61K2039/6056 , A61K2039/627 , A61P31/18 , C07K14/005 , C07K16/2878 , C07K2317/24 , C07K2317/732 , C07K2319/02 , C07K2319/40 , C12N7/00 , C12N2740/16134 , C12N2740/16171
摘要： Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
-
公开(公告)号：US10286058B2
公开(公告)日：2019-05-14
申请号：US15111357
申请日：2015-01-13
发明人： SangKon Oh , Sandra Zurawski , Gerard Zurawski
IPC分类号： A61K39/12 , A61K39/395 , C07K14/025 , C07K16/28 , C07K14/005 , C12N7/00 , A61K39/00
摘要： Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV 16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.
-
公开(公告)号：US10167339B2
公开(公告)日：2019-01-01
申请号：US15501526
申请日：2015-08-03
发明人： Yong-Jun Liu , Sandra Zurawski , SangKon Oh , Shino Hanabuchi , Haruyuki Fujita , Hideki Ueno , Patrick Blanco , Hyemee Joo
IPC分类号： A61K39/395 , A61K39/00 , C07K16/28
摘要： Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-α and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.
-
-
-
-
-
-
-
-
-
搜索结果
33 条记录 (耗时 0.031 秒)
